Accenture announced a strategic investment in Ryght AI on December 11, 2025, adding a new partner to its portfolio of AI‑driven solutions for the life‑sciences industry.
The terms of the investment were not disclosed, but the move is part of Accenture Ventures’ broader strategy to acquire or partner with companies that can accelerate drug development. Ryght AI has previously raised more than $9 million in capital, and its agentic AI platform—known as the AI Site Twin—creates dynamic digital replicas of clinical research sites to improve site selection, patient enrollment, and feasibility forecasting.
By embedding Ryght AI’s technology into its consulting and technology services, Accenture aims to shorten clinical‑trial activation timelines from months to weeks, reduce the risk of site underperformance, and lower overall development costs for sponsors and contract research organizations. The platform’s ability to analyze historical performance, patient demographics, and operational data in real time is expected to give Accenture’s life‑sciences clients a competitive edge in a market where trial delays and high costs are major bottlenecks.
The investment aligns with Accenture’s AI‑driven transformation strategy, which has seen recent commitments to companies such as Anthropic, WEVO, and Nvidia. By combining its deep industry expertise with Ryght AI’s specialized platform, Accenture seeks to expand its footprint in the high‑growth life‑sciences sector and reinforce its positioning as a “reinvention partner of choice.”
Petra Jantzer, Senior Managing Director and Global Lead of Life Sciences at Accenture, said, “Generative and agentic AI are transforming the foundation of clinical research. With our investment in Ryght AI, we’re giving our life‑sciences clients the ability to fully leverage operational and scientific data and bring life‑changing therapies to market faster, more efficiently and with greater precision.” Simon Arkell, CEO of Ryght AI, added, “This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life‑sciences companies reimagine how clinical trials are planned, launched and managed—accelerating the journey from discovery to treatment.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.